drugset / Trial / NCT03479372

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

NCT03479372

Phase 1/2 Completed 51 enrolled PanOptica, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Double-masked, uncontrolled, multi-center, study in which participants will be randomized to one of 3 doses of topical ocular PAN 90806 administered once daily for 12 weeks.

Timeline

Start
2018-04-26
Primary completion
2019-05-27
Completion
2019-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject OSI-632 Small molecule Topical